Literature DB >> 15956808

Survival of patients with amyotrophic lateral sclerosis in a population-based registry.

A Millul1, E Beghi, G Logroscino, A Micheli, E Vitelli, A Zardi.   

Abstract

OBJECTIVE: To evaluate the survival of patients with amyotrophic lateral sclerosis (ALS) in an Italian population and to assess the effects of selected prognostic indicators on survival.
BACKGROUND: Median survival of ALS patients has been reported to range between 12 and 23 months from diagnosis and between 23 and 36 months from onset of symptoms. Although several negative prognostic factors have been identified, the overall picture still needs clarification.
METHODS: We included patients enrolled in an Italian ALS Regional Register (population 4,529,003) during the calendar year 1998. The diagnosis was confirmed by an ad hoc committee using the original El Escorial criteria. Each case was regularly followed up until death or December 31, 2002, whichever came first. Survival was assessed with the Kaplan-Meier method in the whole sample, by level of diagnostic certainty, and by selected prognostic indicators (age, sex, bulbar or spinal onset, and disease duration). Multivariate analysis was done with the Cox proportional hazard function.
RESULTS: The sample comprised 79 patients (33 female; 46 male) aged 28-85 years (mean age 64.4 years). Onset of symptoms was bulbar in 30% of cases. Mean symptom duration at diagnosis was 13.3 months. ALS was definite in 43%, probable in 29%, possible in 6%, and suspected in 22%. By December 31, 2002, 56 cases (71%) had died. The cumulative probability of surviving after diagnosis was 78% at 12 months, 56% at 24 months, and 32% at 48 months. Median survival from onset was 39.2 months and from diagnosis 30.6 months. Multivariate analysis confirmed definite ALS at diagnosis and older age as adverse prognostic factors.
CONCLUSIONS: Survival of ALS patients in the present sample was slightly longer than previously reported. Better palliative care and supportive treatment may explain the difference. Older age and the presence of definite ALS at diagnosis are poor prognostic predictors. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 15956808     DOI: 10.1159/000086353

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  27 in total

Review 1.  The present and the future of neuroimaging in amyotrophic lateral sclerosis.

Authors:  F Agosta; A Chiò; M Cosottini; N De Stefano; A Falini; M Mascalchi; M A Rocca; V Silani; G Tedeschi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

Review 2.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

3.  Amyotrophic lateral sclerosis: clinical management and research update.

Authors:  Jinsy Andrews
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

4.  The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study.

Authors:  Alok K Sharma; Hemangi M Sane; Amruta A Paranjape; Nandini Gokulchandran; Anjana Nagrajan; Myola D'sa; Prerna B Badhe
Journal:  Am J Stem Cells       Date:  2015-03-15

5.  Diffusion tensor imaging in amyotrophic lateral sclerosis--increased sensitivity with optimized region-of-interest delineation.

Authors:  T Prokscha; J Guo; S Hirsch; J Braun; I Sack; T Meyer; M Scheel
Journal:  Clin Neuroradiol       Date:  2013-05-14       Impact factor: 3.649

6.  Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS.

Authors:  Terrell E Brotherton; Yingjie Li; Deborah Cooper; Marla Gearing; Jean-Pierre Julien; Jeffrey D Rothstein; Kevin Boylan; Jonathan D Glass
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

7.  Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population.

Authors:  Marianthi-Anna Kioumourtzoglou; Ryan M Seals; Liselotte Himmerslev; Ole Gredal; Johnni Hansen; Marc G Weisskopf
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-05-06       Impact factor: 4.092

8.  Kinesin-associated protein 3 (KIFAP3) has no effect on survival in a population-based cohort of ALS patients.

Authors:  Bryan J Traynor; Michael Nalls; Shiao-Lin Lai; Raphael J Gibbs; Jennifer C Schymick; Sampath Arepalli; Dena Hernandez; Marcel P van der Brug; Janel O Johnson; Allissa Dillman; Mark Cookson; Cristina Moglia; Andrea Calvo; Gabriella Restagno; Gabriele Mora; Adriano Chiò
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

Review 9.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 10.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.